Skip to content
  • Clinical Studies
  • Schedule M
  • Stability Studies
  • Pharma GMP
  • Pharma Tips
  • Pharma Books
  • Pharma Validation
  • Pharma Regulatory

SOP Guide for Pharma

The Ultimate Resource for Pharmaceutical SOPs and Best Practices

  • Home
  • SOP Guidelines
    • SOP Development
    • SOP Training
    • SOP Compliance Monitoring
    • SOP Revision Processes
    • Pharmaceutical SOP templates
    • GMP documentation SOP
    • Data integrity SOP pharma
    • Manufacturing SOP pharmaceutical
    • FDA SOP guidance
    • eQMS SOP workflows
  • Job Safety Analysis (JSA)
    • Oral Dosage Forms (Tablets & Capsules)
    • Oral Liquid Dosage Forms (Syrups, Elixirs, Suspensions, Emulsions)
    • Powder and Granule Dosage Forms
    • Topical Dosage Forms (Creams, Ointments, Gels, Lotions, Pastes)
    • Transdermal Dosage Forms (Patches)
  • Standard Test Procedures (STP)
  • GMP Audit Findings
    • Non-Compliance
      • SOP Absence
      • Revision Control
      • Non-Adherence
      • Poor Writing
      • Training Failure
      • Data Integrity Gaps
      • Mismatch Between SOPs and Practice
      • Critical Operations
      • Regulatory Change
      • Emergency Changes
      • Third-Party SOPs
      • Inspection Readiness
      • Deviation Handling
      • CAPA Integration
      • Validation Alignment
      • System Integration
      • Uncontrolled Distribution
      • SOP Implementation Gaps
      • SOP Alignment with Validation
      • Change Control Linkage
  • Toggle search form

BA-BE Studies: SOP for Data Integrity in Bioanalytical Labs – V 2.0

Posted on By

BA-BE Studies: SOP for Data Integrity in Bioanalytical Labs – V 2.0

Standard Operating Procedure for Ensuring Data Integrity in Bioanalytical Laboratories during BA/BE Studies

Department BA-BE Studies
SOP No. SOP/BA-BE/185/2025
Supersedes SOP/BA-BE/185/2022
Page No. Page 1 of 10
Issue Date 17/04/2025
Effective Date 20/04/2025
Review Date 17/04/2026

1. Purpose

To establish a comprehensive procedure for maintaining data integrity in all bioanalytical processes supporting bioavailability/bioequivalence (BA/BE) studies, ensuring compliance with regulatory standards and ALCOA+ principles.

2. Scope

This SOP applies to all personnel, electronic systems, data collection tools, and documentation processes within the bioanalytical laboratory involved in BA/BE studies.

3. Responsibilities

  • Analysts: Ensure timely, complete, and accurate data
recording and follow Good Documentation Practices (GDP).
  • Data Reviewers: Verify data accuracy, authenticity, and traceability before approval.
  • System Administrators: Manage access control, backups, and audit trails in analytical software systems.
  • QA Unit: Conducts periodic audits for data integrity compliance and investigates deviations.
  • 4. Accountability

    The Head of Bioanalytical Laboratory is accountable for enforcing data integrity practices and ensuring ongoing adherence to regulatory expectations across all BA/BE studies.

    5. Procedure

    5.1 ALCOA+ Principles Implementation

    1. Ensure that all data generated meets the ALCOA+ criteria:
      • Attributable: Clearly identify who performed the action.
      • Legible: Data must be readable and permanent.
      • Contemporaneous: Record data at the time of activity.
      • Original: Maintain original source data.
      • Accurate: Ensure correctness and reliability.
      • Complete, Consistent, Enduring, Available – Additional (+) principles to support lifecycle integrity.

    5.2 Data Entry and Review

    1. Ensure all data entries in logbooks, software, and LIMS are dated, signed, and attributable to the person performing the activity.
    2. Use ink for handwritten entries; never use pencil or correction fluid.
    3. Any corrections must be made using a single line strike-through, signed, dated, and justified.
    4. Electronic data shall be reviewed using audit trails, reviewer comments, and version histories.

    5.3 Electronic System Controls

    1. Access to analytical instruments, LIMS, and CDS shall be restricted via unique user IDs and passwords.
    2. System administrators must maintain access level logs and periodically review them.
    3. Audit trails shall be enabled for all critical data actions including acquisition, modification, and deletion.
    4. Perform daily backup of all electronic data and store copies in secure, validated repositories.

    5.4 Sample and Reagent Traceability

    1. Label all reagents, samples, and solutions with:
      • Name, concentration, preparation date, expiry date, and prepared by
    2. Track sample movement using Annexure-1: Sample Movement Log.

    5.5 Training and Awareness

    1. All personnel shall receive annual training on data integrity principles and documentation practices.
    2. Training records shall be maintained as per Annexure-2: Training Record Log.

    5.6 Deviation and Investigation Management

    1. Any suspected data manipulation, backdating, or falsification must be immediately reported to QA.
    2. QA shall investigate and document findings using Annexure-3: Data Integrity Incident Form.
    3. Corrective and Preventive Actions (CAPA) must be initiated and tracked to closure.

    5.7 Data Retention and Archival

    1. Retain raw data, audit trails, logbooks, and reports for a minimum of 5 years or as per regulatory requirements.
    2. Archived data should be stored in a manner that prevents tampering, loss, or degradation.

    6. Abbreviations

    • BA/BE: Bioavailability/Bioequivalence
    • LIMS: Laboratory Information Management System
    • CDS: Chromatography Data System
    • GDP: Good Documentation Practice
    • CAPA: Corrective and Preventive Action
    • QA: Quality Assurance

    7. Documents

    1. Sample Movement Log – Annexure-1
    2. Training Record Log – Annexure-2
    3. Data Integrity Incident Form – Annexure-3

    8. References

    • MHRA GxP Data Integrity Guidance
    • FDA 21 CFR Part 11
    • ICH Q10: Pharmaceutical Quality System
    • WHO TRS No. 996, Annex 5 – Data Integrity

    9. SOP Version

    Version: 2.0

    10. Approval Section

    Prepared By Checked By Approved By
    Signature
    Date
    Name
    Designation
    Department

    11. Annexures

    Annexure-1: Sample Movement Log

    Sample ID Date From Location To Location Moved By Verified By
    PL-212 15/04/2025 Freezer -20°C LC-MS Lab Rajesh Kumar Sunita Reddy

    Annexure-2: Training Record Log

    Employee Name Training Topic Date Trainer Remarks
    Ajay Verma Data Integrity in BA/BE 10/03/2025 QA Officer Completed

    Annexure-3: Data Integrity Incident Form

    Incident ID Date Reported By Description Investigation Summary CAPA Reference
    DI-001 14/04/2025 QA Auditor Backdated chromatogram found Confirmed by audit trail CAPA-009

    Revision History:

    Revision Date Revision No. Details Reason Approved By
    01/01/2022 1.0 Initial Release New SOP QA Head
    17/04/2025 2.0 Expanded ALCOA+ framework and annexures added Regulatory Update QA Head
    See also  BA-BE Studies: SOP for Clinical Site Monitoring Visits - V 2.0
    BA-BE Studies V 2.0 Tags:Absolute bioavailability, AUC (area under the curve), Bioavailability, Bioequivalence, Bioequivalence criteria, CDSCO bioequivalence norms, Clinical trial registration, Cmax (maximum concentration), Confidence interval %, Crossover study design, EMA bioequivalence requirements, Ethics committee approval, FDA bioequivalence guidelines, Generic drug approval, Good Clinical Practice (GCP), Good Laboratory Practice (GLP), Half-life (t½), ICH E(R) compliance, In vitro dissolution, In vivo studies, Informed consent process, Pharmacodynamics, Pharmacokinetics, Randomized controlled trial, Regulatory submission process, Relative bioavailability, Sample size calculation, Therapeutic equivalence, Tmax (time to maximum concentration), Washout period

    Post navigation

    Previous Post: Biosimilars: SOP for Deviation Management During Upstream Runs – V 2.0
    Next Post: Elixir Department: SOP for Mixing Time Validation – V 2.0

    Standard Operating Procedures V 1.0

    • Aerosols
    • Analytical Method Development
    • Bioequivalence Bioavailability Study
    • Capsule Formulation
    • Clinical Studies
    • Creams
    • Data Integrity
    • Dental Dosage Forms
    • Drug Discovery
    • Environment, Health and Safety
    • Formulation Development
    • Gels
    • Good Distribution Practice
    • Good Warehousing Practices
    • In-Process Control
    • Injectables
    • Liquid Orals
    • Liposome and Emulsion Formulations
    • Lotions
    • Lyophilized Products
    • Maintenance Dept.
    • Medical Devices
    • Metered-Dose Inhaler
    • Microbiology Testing
    • Nanoparticle Formulation
    • Nasal Spray Formulations
    • Nebulizers
    • Ocular (Eye) Dosage Forms
    • Ointments
    • Otic (Ear) Dosage Forms
    • Pharmacovigilance
    • Powder & Granules
    • Purchase Departments
    • Quality Assurance
    • Quality Control
    • Raw Material Stores
    • Regulatory Affairs
    • Tablet Manufacturing
    • Rectal Dosage Forms
    • Transdermal Patches
    • Vaginal Dosage Forms
    • Validations and Qualifications

    Read SOPs in your Language:

     - 
    Bengali
     - 
    bn
    English
     - 
    en
    Gujarati
     - 
    gu
    Hindi
     - 
    hi
    Malayalam
     - 
    ml
    Marathi
     - 
    mr
    Punjabi
     - 
    pa
    Tamil
     - 
    ta
    Telugu
     - 
    te

    NEW! Revised SOPs – V 2.0

    • Aerosols V 2.0
    • Analytical Method Development V 2.0
    • API Manufacturing V 2.0
    • BA-BE Studies V 2.0
    • Biosimilars V 2.0
    • Capsules V 2.0
    • Creams V 2.0
    • Elixers V 2.0
    • Gels V 2.0
    • Injectables V 2.0
    • Ointments V 2.0
    • Raw Material Warehouse V 2.0
    • Tablet Manufacturing V2.0

    New Publication: A must for All.

    Copyright © 2026 SOP Guide for Pharma.

    Powered by PressBook WordPress theme

    Go to mobile version